ELUCIDATING RESISTANCE MECHANISM TO PARP INHIBITORS FOR THE DEVELOPMENT OF NOVEL THERAPEUTIC APPROACHES IN HIGH-GRADE SEROUS OVARIAN CANCER

被引：1
|
作者：
Kulbe, Hagen [1 ]
Kassuhn, Wanja [2 ,3 ,4 ,5 ]
Ringel, Frauke [2 ,3 ,4 ,5 ]
Welsch, Gabriele [2 ,3 ,4 ,5 ]
Treffkorn, Peggy [2 ,3 ,4 ,5 ]
Taube, Eliane [2 ,3 ,4 ,5 ]
Horst, David [2 ,3 ,4 ,5 ]
Sehouli, Jalid [2 ,3 ,4 ,5 ]
Braicu, Elena [2 ,3 ,4 ,5 ]
机构：
[1] Charite Univ Med Berlin, Dept Gynecol, Campus Virchow Clin, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Free Univ Berlin, Berlin, Germany
[4] Humboldt Univ, Berlin, Germany
[5] Berlin Inst Hlth, Berlin, Germany
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2020年 / 30卷
关键词：
D O I：
10.1136/ijgc-2020-ESGO.133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
416
引用
收藏
页码：A79 / A79
页数：1
相关论文
共 50 条
  • [41] Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
    Vendrell, Julie A.
    Ban, Iulian O.
    Solassol, Isabelle
    Audran, Patricia
    Cabello-Aguilar, Simon
    Topart, Delphine
    Lindet-Bourgeois, Clothilde
    Colombo, Pierre-Emmanuel
    Legouffe, Eric
    D'Hondt, Veronique
    Fabbro, Michel
    Solassol, Jerome
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [42] PARP vs PARG: Exploring Poly (ADP-ribose) glycohydrolase inhibitors in the context of high-grade serous ovarian cancer.
    Taylor, Stephen S.
    Tighe, Anthony
    Pillay, Nisha
    Bah, Nourdine
    Nelson, Louisa
    James, Dominic
    Clamp, Andrew
    Edmondson, Richard
    Jayson, Gordon
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 78 - 78
  • [43] Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma.
    Vandenberg, Cassandra J.
    Ho, Gwo-Yaw
    Nesic, Ksenija
    Swisher, Elizabeth M.
    Grimmond, Sean M.
    Wakefield, Matthew J.
    Barker, Holly E.
    Bowtell, David D.
    Scott, Clare L.
    CANCER RESEARCH, 2021, 81 (13)
  • [44] Loss of TGFβ signaling increases alternative end-joining and could sensitize high-grade serous ovarian cancer to PARP inhibitors
    Guix, Ines
    Liu, Qi
    Palomero, Luis
    Moore, Jade
    Pujana, Miquel Angel
    Barcellos-Hoff, Mary Helen
    CANCER RESEARCH, 2020, 80 (16)
  • [45] Utilizing colforsin as a novel therapeutic for high grade serous ovarian cancer treatment
    Knarr, Matthew
    Reavis, Hunter
    Mitchell, Marilyn
    Drapkin, Ronny
    CANCER RESEARCH, 2022, 82 (12)
  • [46] Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
    Criscuolo, Daniela
    Avolio, Rosario
    Parri, Matteo
    Romano, Simona
    Chiarugi, Paola
    Matassa, Danilo Swann
    Esposito, Franca
    ANTIOXIDANTS, 2022, 11 (08)
  • [47] Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
    Wu, Huan
    Li, Rongrong
    Zhang, Zhiwei
    Jiang, Huiyang
    Ma, Hanlin
    Yuan, Cunzhong
    Sun, Chenggong
    Li, Yingwei
    Kong, Beihua
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (01)
  • [48] Platinum Resistance in High-Grade Serous Ovarian Cancer: an Intratumoral Collagen Fiber Implication
    Pavanello, Marina
    Natal, Rodrigo de Andrade
    Ramalho, Susana
    Vassallo, Jose
    de Angelo Andrade, Liliana Aparecida
    Derchain, Sophie
    Sarian, Luis Otavio
    FASEB JOURNAL, 2016, 30
  • [49] Drug resistance in end-stage high-grade serous ovarian cancer.
    Christie, Elizabeth L.
    Alsop, Kathryn
    Au-Yeung, George
    Pandey, Ahwan
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 17 - 17
  • [50] The genomic profile of high-grade serous ovarian cancer and its association with platinum resistance
    Montemorano, Lauren
    Lang, Jessica
    Shultz, Zoey
    Farooque, Alma
    Hyun, Meredith
    Chappell, Richard
    Hartenbach, Ellen
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S290 - S291
12345